Source: DGNews  |  Posted 8 years ago

By Alison Palkhivala

LYON, FRANCE -- April 29, 2003 -- Pegvisomant is an effective treatment for acromegaly, regardless of whether patients have been treated in the past or how they responded to previous therapy.

Dr. Peter J. Trainer, from the department of endocrinology, Christie Hospital, Manchester, England, and colleagues investigated whether response to pegvisomant in patients with acromegaly can be predicted by previous response to other therapies.

Results were presented in a poster here on April 29th at the 6th European Congress of Endocrinology.

Pegvisomant is a pegylated analog of human growth hormone that acts as a competitive growth hormone receptor antagonist. The research was conducted in collaboration with Pharmacia Corporation, manufacturers of pegvisomant under the trade name Somavert